NEW YORK--(BUSINESS WIRE)--Oct. 25, 2005--Antigenics Inc. (NASDAQ: AGEN) today announced that it has initiated a multicenter Phase 1 clinical trial of Aroplatin(TM), an investigational liposomal formulation of a proprietary platinum chemotherapeutic. The dose-ranging study will evaluate the safety and pharmacokinetic profile of Aroplatin, which has been reformulated to enhance the drug's activation and stability.
